<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03070847</url>
  </required_header>
  <id_info>
    <org_study_id>txa01</org_study_id>
    <nct_id>NCT03070847</nct_id>
  </id_info>
  <brief_title>Low vs. Very Low Dose of Prophylactic Tranexamic Acid for Bleeding Reduction During Rhinoplasty</brief_title>
  <official_title>Impact of Prophylactic Tranexamic Acid on Intra and Postoperational Bleeding Reduction in Patients Undergoing Rhinoplasty Surgery. Low (10mg/kg) and Very Low (5mg/kg) Dose Comparison</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bartłomiej Wódarski</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre of Postgraduate Medical Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether very low dose of preoperative tranexamic
      acid (5mg/kg) is as effective as low dose (10mg/kg) for intraoperational bleeding reduction
      in patients undergoing elective rhinoplasty surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background

      Tranexamic acid is a drug registered for bleeding prevention and reduction. It is on the
      World Health Organisation (WHO) 'essential drugs list'. Preoperative tranexamic acid efficacy
      is well proved for doses between 10 and 40 mg/kg and last years and decades publications
      showed that 'low dose' (10mg/kg) is as efficient as higher doses but connected with less
      adverse effects.

      Objectives

      To determine whether 5 mg/kg dose is as effective as commonly used 10mg/kg dose in
      intraoperational bleeding reduction.

      Methodology All patients would be randomised into one of two arms - low and very low dose.
      Patients, investigators and caregivers would be blinded. Patients would receive intravenous
      bolus of tranexamic acid at 15 minutes before admission to operation theatre in a dose
      dependent on the study arm. General, intravenous anesthesia (total intravenous anesthesia)
      would be performed due to hospital standards. At the end of the surgery total blood volume
      and adverse effects would be noted. Surgeon would asses surgical field in the Fromm scale.

      The survey is planned for a two years timespan or until 50 patients have enrolled (25 for
      each arm).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blinded (participant, care provider, investigator). Computer block randomisation tool will be used (randomisation.com 1 block, 50 subjects per block), 50 notes with '5 mg/kg' or '10 mg/kg' will be put into sealed envelopes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperational bleeding</measure>
    <time_frame>during rhinoplasty</time_frame>
    <description>it would be assessed at the end of the surgery by measuring blood volume in the suction device and net weight of all surgical material. (precision balance - 2 mg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>during rhinoplasty and first day after surgery</time_frame>
    <description>any adverse effects connected with tranexamic acid usage would be noted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgical field assesment</measure>
    <time_frame>during rhinoplasty</time_frame>
    <description>Fromm scale of surgical field would be used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgery length</measure>
    <time_frame>during rhinoplasty</time_frame>
    <description>surgical procedure length would be noted</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bleeding Reduction</condition>
  <arm_group>
    <arm_group_label>Very low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Dose: 5mg/kg</description>
    <arm_group_label>Very low dose</arm_group_label>
    <other_name>Exacyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Dose: 10mg/kg</description>
    <arm_group_label>Low dose</arm_group_label>
    <other_name>Exacyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride</intervention_name>
    <description>Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.</description>
    <arm_group_label>Very low dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 y.o.

          -  American Society of Anesthesiologists Physical Status Classification (ASA) 1-2

          -  signed informed consent form after reading the information about the study and talking
             with one of the investigators

        Exclusion Criteria:

          -  pregnancy

          -  known allergies for tranexamic acid or any other substance in Exacyl

          -  deep vein thrombosis

          -  Hormone Replacement Therapy or oral contraceptive usage

          -  anticoagulants usage

          -  obesity - BMI (body mass index) &gt;30 kg/m2

          -  renal disease, as glomerular filtration rate (GFR) &lt;60 ml/min/1,73 m*m

          -  seizures or epilepsy in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bartłomiej Wódarski, MD</last_name>
    <phone>505064789</phone>
    <email>barwoda@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paweł Krzęczko, MD</last_name>
    <email>pawkrze@o2.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny im. prof. W. Orłowskiego w Warszawie</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-416</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartłomiej Wódarski, MD</last_name>
      <phone>505064789</phone>
      <email>barwoda@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Paweł Krzęczko, MD</last_name>
      <email>pawkrze@o2.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Paweł Krzęczko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamil Radzikowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Małgorzata Malec-Milewska, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centre of Postgraduate Medical Education</investigator_affiliation>
    <investigator_full_name>Bartłomiej Wódarski</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>rhinoplasty</keyword>
  <keyword>bleeding reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

